Display options
Cite
Schneeweiss A, Ruckhäberle E, Huober J. Chemotherapy for Metastatic Breast Cancer - An Anachronism in the Era of Personalised and Targeted Oncological Therapy?. Geburtshilfe Frauenheilkd. 2015;75(6):574-583doi: 10.1055/s-0035-1546150.
Schneeweiss, A., Ruckhäberle, E., & Huober, J. (2015). Chemotherapy for Metastatic Breast Cancer - An Anachronism in the Era of Personalised and Targeted Oncological Therapy?. Geburtshilfe und Frauenheilkunde, 75(6), 574-583. https://doi.org/10.1055/s-0035-1546150
Schneeweiss, A, et al. "Chemotherapy for Metastatic Breast Cancer - An Anachronism in the Era of Personalised and Targeted Oncological Therapy?." Geburtshilfe und Frauenheilkunde vol. 75,6 (2015): 574-583. doi: https://doi.org/10.1055/s-0035-1546150
Schneeweiss A, Ruckhäberle E, Huober J. Chemotherapy for Metastatic Breast Cancer - An Anachronism in the Era of Personalised and Targeted Oncological Therapy?. Geburtshilfe Frauenheilkd. 2015 Jun;75(6):574-583. doi: 10.1055/s-0035-1546150. PMID: 26166838; PMCID: PMC4490921.
Copy Download .nbib Format: NLM
Share it on

Geburtshilfe Frauenheilkd. 2015 Jun;75(6):574-583. doi: 10.1055/s-0035-1546150.

Chemotherapy for Metastatic Breast Cancer - An Anachronism in the Era of Personalised and Targeted Oncological Therapy?.

Geburtshilfe und Frauenheilkunde

A Schneeweiss, E Ruckhäberle, J Huober

Affiliations

  1. Nationales Centrum für Tumorerkrankungen, Universitätsklinikum Heidelberg, Heidelberg.
  2. Frauenklinik, Universitätsklinikum Düsseldorf, Düsseldorf.
  3. Brustzentrum und Gynäkologisches Krebszentrum, Universitätsfrauenklinik Ulm, Ulm.

PMID: 26166838 PMCID: PMC4490921 DOI: 10.1055/s-0035-1546150

Abstract

Based on the findings of modern molecular biology, breast cancer is nowadays considered to be a heterogeneous disease. This leads to the objective of an individualised, more patient-oriented therapy. A series of target molecules for this purpose has already been identified. The principle of targeted oncological therapy was realised decades ago with the introduction of endocrine therapy for patients with hormone receptor-positive tumours. The modern therapy for HER2-positive tumours is a further example for the translation of targeted therapy into clinical routine. For patients with HER2-negative metastatic breast cancer, to date two targeted drugs, bevacizumab and everolimus, are available for routine clinical use. Many other substances are still undergoing clinical development. However, validated predictive markers to aid in therapeutic decision-making and therapy control are still lacking. Chemotherapy constitutes an effective palliative therapy with proven efficacy for the patients. In this process strategies have also been realised for a targeted therapy against tumour cells with the help of chemotherapeutic agents such as, for example, the intracellular activation of the prodrug capecitabine or the active albumin-mediated transport of nab-paclitaxel which leads to higher peri- and intratumoural enrichments. The continuing unchanged relevance of chemotherapy is often underestimated in the current discussions and will be comprehensively evaluated in this review.

Keywords: HER2-negative; HER2-positive; chemotherapy; metastatic breast cancer; targeted therapy

References

  1. Cochrane Database Syst Rev. 2009 Apr 15;(2):CD003372 - PubMed
  2. Curr Med Res Opin. 2013 Feb;29(2):117-25 - PubMed
  3. Ann Oncol. 2004 Mar;15(3):440-9 - PubMed
  4. J Clin Oncol. 2010 Jul 10;28(20):3239-47 - PubMed
  5. N Engl J Med. 2012 Feb 9;366(6):520-9 - PubMed
  6. Breast Cancer Res. 2010;12(5):R75 - PubMed
  7. N Engl J Med. 2012 Nov 8;367(19):1783-91 - PubMed
  8. Ann Oncol. 2014 Dec;25(12 ):2357-62 - PubMed
  9. Lancet Oncol. 2014 Jun;15(7):747-56 - PubMed
  10. J Clin Oncol. 2005 Aug 20;23(24):5542-51 - PubMed
  11. J Clin Oncol. 1999 Mar;17(3):846-54 - PubMed
  12. J Clin Oncol. 2005 Nov 1;23(31):7794-803 - PubMed
  13. Lancet. 2011 Mar 12;377(9769):914-23 - PubMed
  14. Breast. 2011 Dec;20(6):485-90 - PubMed
  15. Lancet Oncol. 2012 Jan;13(1):25-32 - PubMed
  16. Nature. 2000 Aug 17;406(6797):747-52 - PubMed
  17. J Oncol. 2012;2012:417673 - PubMed
  18. Mol Cancer Ther. 2005 Jul;4(7):1086-95 - PubMed
  19. J Clin Oncol. 1996 Sep;14(9):2552-9 - PubMed
  20. J Clin Oncol. 2012 Jul 20;30(21):2585-92 - PubMed
  21. Br J Cancer. 2005 Aug 8;93(3):293-301 - PubMed
  22. Oncologist. 2010;15(2):122-9 - PubMed
  23. J Clin Oncol. 2008 Apr 20;26(12):1980-6 - PubMed
  24. Nat Rev Clin Oncol. 2013 Apr;10(4):191-210 - PubMed
  25. Breast Cancer Res Treat. 2014 Feb;143(3):507-15 - PubMed
  26. Clin Breast Cancer. 2012 Oct;12(5):313-21 - PubMed
  27. J Clin Oncol. 2011 Jun 1;29(16):2144-9 - PubMed
  28. Oncologist. 2008 Jun;13(6):620-30 - PubMed
  29. Cochrane Database Syst Rev. 2005 Apr 18;(2):CD003366 - PubMed
  30. Ann Oncol. 2012 May;23(5):1164-9 - PubMed
  31. J Clin Oncol. 2004 Jun 15;22(12):2313-20 - PubMed
  32. Ann Oncol. 2011 Jun;22(6):1308-17 - PubMed
  33. Cancer. 2002 Jan 1;94(1):25-36 - PubMed
  34. Oncology (Williston Park). 2011 Oct;25(11):1014-25 - PubMed
  35. J Clin Oncol. 2005 Jul 1;23(19):4265-74 - PubMed
  36. Lancet Oncol. 2007 Mar;8(3):219-25 - PubMed
  37. BMC Cancer. 2007 Aug 08;7:153 - PubMed
  38. J Clin Oncol. 2013 May 10;31(14):1719-25 - PubMed
  39. N Engl J Med. 2007 Dec 27;357(26):2666-76 - PubMed
  40. J Clin Oncol. 1995 Apr;13(4):929-34 - PubMed
  41. Oncologist. 2010;15(9):924-34 - PubMed
  42. J Clin Oncol. 2009 Nov 20;27(33):5529-37 - PubMed
  43. Cancer J. 2001 Sep-Oct;7(5):377-87 - PubMed
  44. J Clin Oncol. 1995 Oct;13(10):2567-74 - PubMed
  45. J Clin Oncol. 2010 Dec 10;28(35):5132-9 - PubMed
  46. N Engl J Med. 2001 Mar 15;344(11):783-92 - PubMed
  47. J Clin Oncol. 2008 Apr 1;26(10):1642-9 - PubMed
  48. Anticancer Res. 2014 Nov;34(11):6609-15 - PubMed
  49. Lancet Oncol. 2014 Mar;15(3):267-74 - PubMed
  50. Ann Oncol. 2010 Sep;21(9):1765-71 - PubMed
  51. Science. 2013 Mar 29;339(6127):1546-58 - PubMed
  52. Anticancer Drugs. 2006 Jun;17(5):587-95 - PubMed
  53. Nature. 2013 May 2;497(7447):108-12 - PubMed
  54. J Clin Oncol. 2002 Jun 15;20(12):2812-23 - PubMed
  55. Cochrane Database Syst Rev. 2005 Apr 18;(2):CD003372 - PubMed
  56. J Clin Oncol. 2003 Feb 15;21(4):588-92 - PubMed
  57. N Engl J Med. 2006 Dec 28;355(26):2733-43 - PubMed
  58. J Clin Oncol. 2015 Feb 20;33(6):594-601 - PubMed
  59. J Clin Oncol. 2011 Nov 10;29(32):4286-93 - PubMed
  60. Lancet Oncol. 2013 Sep;14(10):933-42 - PubMed
  61. Cochrane Database Syst Rev. 2004 Oct 18;(4):CD003367 - PubMed
  62. J Clin Oncol. 2009 Aug 1;27(22):3611-9 - PubMed
  63. Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74 - PubMed
  64. Clin Cancer Res. 2006 Feb 15;12(4):1317-24 - PubMed
  65. Lancet Oncol. 2013 Feb;14(2):125-33 - PubMed
  66. J Clin Oncol. 2015 Jan 1;33(1):13-21 - PubMed
  67. Breast. 2012 Feb;21(1):27-33 - PubMed
  68. Nat Rev Genet. 2012 Nov;13(11):795-806 - PubMed
  69. Cancer Cell. 2012 Mar 20;21(3):309-22 - PubMed
  70. Nat Rev Clin Oncol. 2011 Nov 29;9(1):16-32 - PubMed
  71. J Clin Oncol. 2011 Apr 1;29(10):1252-60 - PubMed

Publication Types